X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator, which is being evaluated for the treatment of platinum-resistant ARID1a-mutated ovarian cancer.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
The collaboration aims to evaluate NXP800, an oral small molecule, in an Investigator-sponsored clinical trial in cholangiocarcinoma. The FDA granted Orphan Drug Designation for the treatment of cholangiocarcinoma.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2023
Details:
NXP900 is a novel inhibitor of the SRC family of kinases with low nanomolar potency against YES1 and SRC. It has demonstrated robust single agent antitumor activity in several in vivo oncological xenograft models.
Lead Product(s): NXP900
Therapeutic Area: Oncology Product Name: NXP900
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The IND has been cleared by the FDA and a Phase 1a dose escalation study is pending commencement.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
NXP900 is a novel inhibitor of the SRC family of kinases with low nanomolar potency against YES1 and SRC. It has demonstrated robust single agent antitumor activity in several in vivo oncological xenograft models.
Lead Product(s): NXP900
Therapeutic Area: Oncology Product Name: NXP900
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers. It is being investigated in platinum-resistant, ARID1a-mutated ovarian carcinoma.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ENGOT
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2023
Details:
The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1a study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical with IND studies ongoing.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
NXP800 is an HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900 is a novel SRC/YES1 kinase inhibitor currently in IND-enabling studies.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
